In a remarkable display of market confidence, Intra-Cellular Therapies Inc. (NASDAQ:ITCI) stock has reached an all-time high, touching a price level of $128.01. According to InvestingPro data, the ...

Intra-Cellular Therapies ITCI signed a definitive agreement with pharma bigwig Johnson & Johnson JNJ. Per the terms, the pharma giant will acquire all outstanding shares of ITCI for $132 per share ...

Intra-Cellular Therapies stock opened at $127.01 on Friday. Intra-Cellular Therapies has a twelve month low of $62.78 and a twelve month high of $128.00. The stock has a market cap of $13.50 ...

Canaccord downgraded Intra-Cellular (ITCI) to Hold from Buy with a price target of $132, up from $119, after Johnson & Johnson (JNJ) agreed ...

In a report released today, Jeffrey Hung from Morgan Stanley maintained a Hold rating on Intra-Cellular Therapies (ITCI – Research Report), ...

Below is Validea's guru fundamental report for INTRA-CELLULAR THERAPIES INC (ITCI). Of the 22 guru strategies we follow, ITCI rates highest using our Value Investor model based on the published ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...